```html

Xanthopsia (Medication‑Induced)

What is Xanthopsia (Medication‑Induced)?

Xanthopsia is a visual disturbance in which objects appear yellow‑tinted or have a pervasive yellow hue. When the condition is medication‑induced, the change in color perception is a side effect of one or more drugs rather than an underlying eye disease.

People with xanthopsia may report that white paper looks cream‑colored, a blue sky appears amber, or that their own skin has a “sun‑kissed” look. The alteration is usually subtle at first but can become disorienting, especially when driving, reading, or performing tasks that require accurate color discrimination.

Because the symptom is linked to drug exposure, it often resolves after the offending medication is reduced, switched, or discontinued. However, the timeline for recovery can vary from days to several weeks, depending on the drug’s half‑life, dosage, and the patient’s metabolism.

Common Causes

Several prescription and over‑the‑counter (OTC) medications have been reported to produce xanthopsia. Below are the most frequently implicated agents and the conditions they treat.

• Digitalis (digoxin, ouabain) – used for heart failure and atrial fibrillation; interferes with retinal photoreceptors.
• Quinine and quinidine – antimalarial and anti‑arrhythmic drugs that can affect cone cell function.
• Phenothiazines (e.g., chlorpromazine, thioridazine) – antipsychotics that may deposit in ocular tissues.
• Topiramate – an anticonvulsant also prescribed for migraines; can cause retinal pigment changes.
• Isotretinoin – oral retinoid for severe acne; known to alter retinal metabolism.
• Phosphodiesterase‑5 inhibitors (e.g., sildenafil) – common for erectile dysfunction; rare cases of color vision shifts.
• Corticosteroids (systemic or high‑dose topical) – long‑term use linked to cataract formation and color distortion.
• Phenylephrine eye drops – OTC decongestants; excessive use can cause temporary yellowing vision.
• Anticholinesterase agents (e.g., pyridostigmine) – used in myasthenia gravis; rare ocular side effects.
• Vitamin A and β‑carotene supplements – high doses can lead to excess retinal pigments and a yellow hue.

Associated Symptoms

Medication‑induced xanthopsia rarely occurs in isolation. Patients often notice additional visual or systemic clues that help clinicians identify the underlying cause.

• Blurred or fluctuating vision
• Glare or halos around lights
• Reduced contrast sensitivity (difficulty distinguishing shades of gray)
• Eye discomfort or dryness
• Headache or eye strain, especially after reading
• Systemic side effects of the culprit drug (e.g., nausea with digoxin, dizziness with quinine)
• Changes in pupil size or light reflexes (particularly with phenothiazines)

When to See a Doctor

Because color perception is essential for safe daily activities, any new or worsening yellow tint should prompt a medical evaluation, especially if any of the following are present:

• Sudden onset of yellow vision without a clear medication change.
• Persistent symptoms lasting longer than a week after stopping or reducing the suspected drug.
• Accompanying visual disturbances such as double vision, loss of peripheral vision, or severe glare.
• Systemic signs of drug toxicity (e.g., irregular heartbeat with digoxin, severe nausea/vomiting with quinine).
• Difficulty performing tasks that require accurate color discrimination (driving, operating machinery, reading medication labels).
• History of eye disease (cataracts, macular degeneration) that could be worsened by the medication.

Early evaluation can prevent permanent retinal damage and allow safe adjustment of therapy.

Diagnosis

Diagnosing medication‑induced xanthopsia involves a combination of patient history, visual testing, and occasionally imaging.

1. Detailed Medication Review

The physician will ask about all prescription drugs, OTC products, herbal supplements, and even dietary sources of vitamin A. Timing of symptom onset relative to drug initiation or dose changes is critical.

2. Ophthalmic Examination

• Visual acuity test – establishes baseline clarity of vision.
• Color vision testing – Ishihara plates or Farnsworth‑Munsell 100 Hue test can detect yellow bias.
• Fundoscopy – evaluates the retina and optic nerve for pigment deposits or drug‑related changes.
• Slit‑lamp examination – looks for corneal or lens opacities that could mimic color shifts.

3. Ancillary Tests (when indicated)

• Optical coherence tomography (OCT) – high‑resolution imaging of retinal layers.
• Electroretinography (ERG) – measures retinal response to light; can reveal functional impairment caused by drugs like digoxin.
• Blood work – serum drug levels (e.g., digoxin), liver/kidney function, and vitamin A concentrations.

4. Differentiation from Other Causes

The clinician will rule out primary ocular conditions (cataract, macular degeneration), neurologic disorders (optic neuritis), and systemic illnesses (liver disease leading to bilirubin‑related yellowing) that can also affect color perception.

Treatment Options

Management focuses on removing the offending agent while protecting visual function.

1. Medication Adjustment

• Dose reduction – often the first step for drugs with a narrow therapeutic window (e.g., digoxin).
• Switching to an alternative – substituting a drug with a lower ocular side‑effect profile (e.g., using a non‑phenothiazine antipsychotic).
• Gradual taper – especially for steroids, to avoid withdrawal and allow retinal recovery.

2. Symptomatic Relief

• Lubricating eye drops – address dryness that can exacerbate visual distortion.
• Anti‑glare glasses – yellow‑tinted lenses can paradoxically reduce glare for some patients, but they should be prescribed after an eye‑care professional’s assessment.
• Screen adjustments – increase text size, contrast, and use “dark mode” to decrease strain.

3. Monitoring & Follow‑up

Regular follow‑up appointments (usually every 2–4 weeks) allow the doctor to track visual recovery and adjust therapy as needed. Repeat color‑vision testing may be performed to confirm improvement.

4. Addressing Underlying Conditions

If the medication is essential (e.g., digoxin for heart failure), the physician may coordinate with a cardiologist to find the safest balance between cardiac control and visual health.

Prevention Tips

While not all cases are avoidable, patients can reduce their risk of medication‑induced xanthopsia by following these practical steps.

• Maintain an updated medication list and share it with every healthcare provider, including dentists and pharmacists.
• Ask about ocular side effects before starting a new prescription, especially for drugs known to affect color vision.
• Never exceed recommended doses** of OTC decongestant eye drops or vitamin A supplements.
• Schedule regular eye exams if you are on long‑term therapy with digitalis, phenothiazines, or high‑dose steroids.
• Report visual changes promptly – early detection limits the chance of permanent retinal alteration.
• Stay hydrated and manage systemic health (e.g., control blood pressure, glucose) as poor systemic circulation can magnify drug toxicity.
• Use protective eyewear when exposed to bright sunlight, especially if you are taking photosensitizing agents like isotretinoin.

Emergency Warning Signs

Seek immediate medical attention if you experience any of the following while on a medication known to affect vision:

• Sudden, severe loss of vision in one or both eyes.
• Persistent double vision (diplopia) or a “curtain” effect over part of the visual field.
• Rapidly worsening yellow tint accompanied by intense headache, nausea, or vomiting.
• Chest pain, irregular heartbeat, or fainting (possible signs of digoxin toxicity).
• Severe allergic reaction—swelling of the face, lips, or throat, or difficulty breathing (may occur with quinine or certain antibiotics).

Call 911 or go to the nearest emergency department if any of these occur.

Key Take‑aways

Xanthopsia caused by medications is an uncommon but reversible visual side effect. Prompt recognition, a thorough medication review, and collaboration between ophthalmologists, primary‑care physicians, and specialists (cardiology, psychiatry, dermatology) are essential for safe management. Patients who stay vigilant about changes in color perception and communicate them to their healthcare team can often prevent long‑term visual consequences.

References:

• Mayo Clinic. “Digoxin side effects.” https://www.mayoclinic.org/digoxin-side-effects (accessed 2026).
• Cleveland Clinic. “Medication‑induced vision changes.” https://my.clevelandclinic.org/health/articles/medication-vision-side-effects.
• National Institutes of Health, Office of Dietary Supplements. “Vitamin A Fact Sheet.” https://ods.od.nih.gov/factsheets/VitaminA-Consumer/.
• World Health Organization. “Guidelines for the safe use of antimalarial drugs.” 2023.
• American Academy of Ophthalmology. “Drug‑induced ocular toxicity.” https://www.aao.org/clinical-statement/drug-induced-ocular-toxicity.

```